ArticleCureus2025
Significant Reduction in Peak Left Ventricular Global Longitudinal Strain in Multiple Myeloma Patients: A Pilot Random Awareness Analysis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and methods Multiple myeloma (MM) is a malignancy associated with cardiovascular complications. Though echocardiography plays a crucial role in assessing cardiac function, its use in the follow-up of MM patients is limited. For this descriptive analysis, we report several recommended objective measures of left ventricular (LV) systolic function, peak global longitudinal strain (PGLS), and right ventricular (RV) systolic function in 147 MM patients at various stages of their treatment who were referred to our echocardiography laboratory at the University of Arkansas for Medical Sciences (Little Rock, AR, USA). Results Mean age was 61 ± 11 years, (range: 30 to 86 years; 82 males). Mean left ventricular ejection fraction (LVEF) was 60 ± 9%, mitral annular (MA) systolic tissue Doppler velocity was 8 ± 2 cm/s, and LV outflow tract velocity time integral (LVOT VTI) was 21 ± 5 cm. Furthermore, RV systolic function measured by tricuspid annular plane systolic excursion (TAPSE) was 2.3 ± 0.4 cm and tricuspid annular (TA) tissue Doppler (TDI) systolic velocity (s') was 13 ± 3 cm/s. These values were reported with regards to normal published standard values. Finally, we identified three distinctive LV PGLS levels, ranging from -7% to -27%. Given the poor correlation, we identified that a total of 74% or 50% of all MM patients with normal LVEF (>55%) had abnormal LV PGLS. No correlation between LVEF and LV PGLS was seen in our study. Conclusions To our knowledge, this is the first study describing these objective measures of cardiac function in MM patients at different stages of treatment. However, additional studies are needed to truly assess asymptomatic changes in cardiac structure during MM treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.